SEPTIN6 mutations point to a senescence-driven cause of congenital neutropenia
Two children with germline SEPTIN6 mutations had already drawn attention because their neutropenia did not stand alone; it was linked to later myelodysplastic syndrome. The new work moves beyond association and tests what the variants do inside human hematopoietic cells. In cultured CD34+ cells, the mutant protein behaved like a driver of marrow failure rather than a passive genetic marker. Cells became enlarged, multinucleated, and functionally depleted, a pattern consistent with stress-induced exhaustion of the stem and progenitor pool.
The biology matters at the bedside because congenital neutropenia often raises the question of whether the marrow is simply underproducing mature cells or whether the stem cell compartment itself is being progressively damaged. Here, the evidence supports the second model. The mutant alleles produced a cellular phenotype that fits premature senescence, with hematopoietic stem and progenitor cells losing their capacity to sustain normal output. In a disorder where chronic neutropenia can precede clonal marrow evolution, that distinction has direct clinical weight.
A gain-of-function mutation, not a silent structural defect
Septins are RAS-like GTP-binding proteins involved in cytoskeletal organization and cell division. In that setting, a mutation can alter how cells divide, shape themselves, and maintain polarity. The investigators examined two germline variants, SEPT6 c.1282T>C and SEPT6 c.1282T>A, and found that both produced a consistent abnormal phenotype in human hematopoietic cells. Rather than merely weakening a scaffold, the mutations appeared to confer a harmful new function that disrupted normal stem cell behavior.
Transgenic expression of the mutant allele in wild-type human CD34+ cells reproduced the defect. Gene editing of the same change led to similar results, strengthening the argument that the phenotype belonged to the variant itself and not to a vector artifact or unrelated background effect. Colony-forming assays showed impaired hematopoietic output, while xenotransplantation into NBSGW mice allowed the investigators to follow the edited cells in vivo. The edited cells did not behave like durable stem cells; they showed evidence of defective maintenance in the hematopoietic system.
A single sentence captures the core finding: the mutant cells aged too fast.
mTOR activation and mitochondrial remodeling converged on the senescent state
The cellular abnormalities were not limited to shape and clonogenic performance. Senescence was accompanied by increased mTOR phosphorylation, a pathway long tied to growth signaling, protein synthesis, and cellular aging. When pharmacologic inhibition of mTOR was applied, senescence defects improved. That result gives the study translational reach because it identifies a pathway that may be mechanistically relevant rather than merely downstream noise.
The mitochondrial data added another layer. Mutant hematopoietic cells showed marked mitochondrial abnormalities, including increased expression of OPA-1, a regulator of mitochondrial fusion, alongside enhanced oxygen consumption during mitochondrial respiration. In practical terms, this means the cells were metabolically altered as well as structurally compromised. Mitochondrial fusion and respiratory reprogramming often travel with cellular stress responses, and in hematopoietic stem cells those changes can erode quiescence and reserve capacity. A stem cell population that burns more fuel and receives persistent growth signals is less likely to remain stable over time.
The findings line up with a broader concept in marrow failure: senescence is not just a hallmark of aging tissue, it can become a disease mechanism in its own right. Here, senescence emerged as a measurable consequence of a defined germline lesion in a pediatric setting. The result helps explain why neutropenia and dysplasia can co-occur in the same patient trajectory.
The secondary somatic SEPTIN6 variant acted as a partial correction
One of the two patients carried an additional somatic mutation, SEPT6 c.43C>T, detected at low allelic fraction in bone marrow. Introducing that somatic variant in cis with GM1 mitigated all observed defects. Enlarged cells, impaired hematopoiesis, and senescence-associated abnormalities were reduced. In the cellular system tested here, the second hit did not worsen disease. It softened it.
That finding is unusual and clinically important. Secondary somatic variants in marrow disorders often raise concern for clonal evolution, but this experiment suggests a compensatory effect in this specific genetic context. The marrow may have been attempting to escape the consequences of the germline defect through a partial functional correction. It is a reminder that not every additional marrow mutation behaves as a classic driver of progression; the biological direction depends on the exact change and where it lands in the protein.
What this means for inherited neutropenia and dysplasia
These experiments establish a gain-of-function mechanism for marrow failure in patients carrying germline SEPTIN6 mutations. They also connect a rare inherited neutropenia syndrome to a defined senescence program involving mTOR signaling and mitochondrial remodeling. For clinicians, the work sharpens the biological framing of a child with persistent neutropenia, abnormal myeloid maturation, and later dysplastic change. The disease is not simply a deficiency of neutrophils; it is a disorder of hematopoietic stem cell integrity.
The study also raises a translational possibility. If mTOR signaling contributes to the senescent phenotype, pathway inhibition may be relevant to future therapeutic exploration. That does not make the finding a treatment recommendation, and the current data remain preclinical. It does, however, provide a rational direction for mechanistic follow-up in inherited marrow failure syndromes where cellular exhaustion is central to disease expression.
The unanswered clinical problem is how often this mechanism operates outside these two patients and whether low-level somatic correction is a recurring adaptive response in similar cases. The work stops at the cellular and xenograft level, so the next step is to determine how these mutant cells behave across broader patient cohorts and whether pathway-targeted intervention can preserve stem cell function without introducing new toxicity.